Physician profile
Paul Ricketts
NPI 1326222928
$9,391.42
in general payments reported to CMS, 2019-2025
36 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $994 · 2021: $1,514 · 2022: $1,533 · 2023: $1,124 · 2024: $1,306 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936 · Education: $78.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,935.73 |
| Education | $78.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,276.45 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $953.47 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $911.74 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $840.59 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $444.33 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $400.15 | 2019-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $316.49 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $191.26 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $148.39 | 2021-2023 | |
| Pfizer INC. | $136.26 | 2020-2025 | |
| Gilead Sciences, INC. | $132.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $124.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $115.60 | 2019-2022 | |
| Celltrion USA INC. | $113.63 | 2024-2025 | Zymfentra, Vegzelma |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $112.02 | 2019-2022 | |
| Braintree Laboratories, INC. | $106.74 | 2021-2023 | Suflave |
| Qol Medical, LLC | $105.36 | 2021-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $104.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $96.42 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $89.10 | 2019-2025 | Rebyota |
| Medtronic, INC. | $66.83 | 2024 | Gi Genius, Interstim |
| Aimmune Therapeutics, INC. | $66.53 | 2024-2025 | Vowst |
| Lilly USA, LLC | $66.00 | 2025 | Omvoh |
| Alfasigma USA, INC. | $51.09 | 2020 | |
| Intra-Sana Laboratories | $43.82 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $41.41 | 2025 | Iqirvo |
| Shire North American Group INC | $38.63 | 2019 | |
| Phathom Pharmaceuticals, INC. | $32.22 | 2024 | Voquezna |
| Alnylam Pharmaceuticals INC. | $28.27 | 2025 | Givlaari |
| Genzyme Corporation | $23.68 | 2025 | |
| Portola Pharmaceuticals, LLC | $21.87 | 2019 | |
| Sandoz INC. | $18.52 | 2025 | |
| Novo Nordisk INC | $18.47 | 2025 | Wegovy |
| W. L. Gore & Associates, INC. | $14.93 | 2022 | |
| Covidien LP | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ricketts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.